According to MarketsandMarkets, the digital biomarkers market is projected to reach USD 15.60 billion by 2030 from USD 6.30 billion in 2025, at a CAGR of 19.9% between 2025 and 2030. The digital biomarkers market is experiencing growth driven by several key factors, including the expansion of wearables & remote monitoring devices and the integration of advanced analytics & AI.
AI-assisted NGS analysis, automated sequencing workflows, and sensitive liquid-biopsy assays are transforming the digital biomarkers market, enabling faster, routine clinical testing. Regulators emphasize companion diagnostics and MRD monitoring, driving the adoption of standardized genomic panels for real-time treatment decisions and disease tracking.
Based on product, the digital biomarkers market is segmented into wearables, mobile-based applications, sensors, and other devices, with wearables accounting for the largest market share, driven by rising smartphone integration, smartwatch sales, and advanced sensors for continuous health monitoring. They excel in capturing physiological data like heart rate, sleep patterns, activity, and biometrics for sleep/movement, cardiovascular, and neurodegenerative applications. Innovations in cuffless monitoring and noninvasive sensing boost their dominance.
Based on type, the market is segmented into physiological biomarkers, idiosyncratic biomarkers, cognitive biomarkers, vocal biomarkers, and other biomarkers. Physiological biomarkers command the highest share by type in the digital biomarkers market, due to their reliability in tracking vital signs like heart rate, blood pressure, glucose, and activity via wearables. They dominate chronic disease management for cardiovascular, metabolic, and respiratory conditions. Advances in noninvasive sensors enhance their clinical validation and adoption.
Based on region, the digital biomarkers market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America commanded the largest regional share in the digital biomarkers market, propelled by advanced healthcare infrastructure, high adoption of wearables and AI-driven tools, and robust regulatory support from the FDA. Leading investments in AI-assisted NGS analysis, automated sequencing workflows, and sensitive liquid-biopsy assays further accelerate innovation. Key hubs like the US foster companion diagnostics and MRD monitoring via standardized genomic panels, enabling real-time clinical decisions.
A key growth driver for digital biomarkers in North America is the rising adoption of NGS-based testing in hospitals, cancer centers, and reference labs, supported by sequencing platforms and bioinformatics tools. Initiatives like Cancer Moonshot, high oncology R&D, and biomarker-driven trials boost genomic profiling demand, with advanced infrastructure and diagnostics firms advancing precision medicine.
